Related Experiment Video
Updated: Aug 9, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Isoflurane therapy for severe refractory status asthmaticus in children
Venkat Shankar1, Kevin B Churchwell, Jayant K Deshpande
1Monroe Carrell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Critical Care Medicine, 5121 B Doctor's Office Tower, TN 37232-9075, Nashville, Tennessee, USA. venkat.shankar@vanderbilt.edu
Objective:
To describe the use of inhaled isoflurane in a series of children with life-threatening asthma.
Design:
Retrospective case series.
Setting:
Pediatric intensive care unit of a tertiary-care children's hospital. Ten children ranging in age from 1 to 16 years with 11 episodes of severe asthma requiring invasive mechanical ventilation in the pediatric intensive care unit over a 5-year period.
Results:
Isoflurane resulted in an improvement in arterial pH and a reduction in partial pressure of arterial carbon dioxide (PaCO(2)) in all the 11 instances. This effect was sustained in 10 cases and led to clinical improvement and rapid weaning from mechanical ventilation. One child failed to show sustained response and was placed on veno-venous extracorporeal membrane oxygenation. One child died secondary to anoxic brain injury sustained prior to hospitalization. Hypotension was the major side effect, and occurred in 8 children necessitating vasopressor support.
Conclusions:
Isoflurane improves arterial pH and reduces partial pressure of arterial carbon dioxide in mechanically ventilated children with life-threatening status asthmaticus who are not responsive to conventional management.
Related Concept Videos
Inhalational Anesthetics: Overview
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Acute Respiratory Failure-III
Acute Respiratory Failure-IV
Inhaled Medications

